Now there's an echinocandin antifungal to treat kids
Cancidas, previously approved for use in adults, can now be applied also to pediatric patients aged three months to 17 years.
Merck's Cancidas (caspofungin acetate), previously approved for use in adults, can now be applied also to pediatric patients aged three months to 17 years. The Whitehouse Station, N.J., firm claims that the approval makes Cancidas the first and only echinocandin therapy approved domestically for the treatment of children with indicated fungal infections. The new expanded labeling is based on data from five clinical trials involving 171 pediatric patients.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
